Prescription Drug Pricing & MCPA Enforcement
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-12 — Health: pharmaceuticals; reports on certain costs and other information associated with prescription drugs; require manufacturers of prescription drugs to file with the department. Creates new act.: cross-connection with prescription-drug-manufacturer-cost-reporting: Both target prescription drug price transparency and manufacturer accountability — one via mandated cost reporting, the other via MCPA enforcement. (novelty: 3)
- 2026-05-13 — Human services: medical services; requirement to prescribe generic medications; provide for. Amends 1939 PA 280 (MCL 400.1 - 400.119b) by adding sec. 109z.: cross-connection with medicaid-generic-medication-requirement: Generic-only prescribing under Medicaid interacts with broader state prescription drug pricing policy. (novelty: 2)
- 2026-07-31 — Attorney General v Eli Lilly and Company: Michigan Supreme Court in Attorney General v Eli Lilly and Company narrowed the MCL 445.904(1)(a) ‘specifically authorized’ exemption to cover only transactions/conduct specifically authorized (not general regulated activity), overruled Smith v Globe Life Insurance and Liss v Lewiston-Richards, and allowed the Attorney General’s insulin list-price MCPA investigation of Eli Lilly to proceed. (novelty: 4)